---
title: Reduce tremor with focused ultrasound
nct_id: NCT07417280
phase: NA
status: RECRUITING
sponsor: University Health Network, Toronto
study_type: INTERVENTIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT07417280"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT07417280"
last_fetched: "2026-05-10T14:07:04.045Z"
source: "Parkinson's Pathways (curated)"
---
# Reduce tremor with focused ultrasound

**Goal (in five words):** Reduce tremor with focused ultrasound

**Official Title:** Clinical Effects of Low-Intensity Focused Ultrasound Neuromodulation in Patients With Neurological and Psychiatric Disorders

**Trial ID:** [NCT07417280](https://clinicaltrials.gov/study/NCT07417280)

## Key Facts

- **Phase:** NA
- **Status:** RECRUITING
- **Study Type:** INTERVENTIONAL
- **Sponsor:** University Health Network, Toronto
- **Target Enrollment:** 50 participants
- **Start Date:** 2025-12-02
- **Completion Date:** 2035-12-31
- **Conditions:** Parkinson's Disease (PD), Essential Tremor, Orthostatic Tremor, Dystonia, Epilepsy, Substance Abuse Disorder, Deep Brain Stimulation
- **Interventions:** LIFUS, Sham LIFUS
- **Intervention Types:** DEVICE

## Summary For Families

Low-intensity focused ultrasound, or LIFUS, is being tested to gently change the activity of the brain circuits that drive Parkinson's motor symptoms like tremor and stiffness, offering a noninvasive complement to medicines or surgery. The device sends focused sound waves through the skull to increase or decrease neuron firing in a targeted spot, it is compared with a sham procedure, and it does not deliver drugs so it can be used alongside levodopa or existing DBS rather than replacing them. Adults 18 to 85 with Parkinson's or other neurological or psychiatric conditions can enroll, but people with prior stroke, dementia or a MoCA under 22, certain implanted metal devices or pacemakers, pregnancy, major uncontrolled psychiatric illness, or serious systemic illness are excluded.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 85 Years
- **Sex:** ALL

### Full Criteria

```
Inclusion Criteria:

* 18-85 years of age
* Patients diagnosed with neurological disorders, (such as epilepsy, brain tumour, movement disorders) or psychiatric disorders (such as substance abuse disorder)
* Patients undergoing medical or surgical treatment (such as DBS) for neurological disorders

Exclusion Criteria:

* History of stroke
* Comorbid dementia
* Scored below 22 on the Montreal Cognitive Assessment (MoCA)
* Has an implanted cardiac pacemaker or implantable cardioverter-defibrillator (ICD)
* Presence of metal implanted in body that is contraindicated in TMS/MRI
* Pregnancy
* Major depression/psychiatric disorder that in the opinion of the Investigator will affect patient's understanding of study procedures and willingness to abide by all procedures during the course of the study
* Receiving a psychotropic medication or taking recreational substances that in the opinion of the investigator will significantly affect safety of the protocol
* Major systemic illness or infection
```

## Locations (1)

- Toronto Western Hospital, 399 Bathurst St, Toronto, Ontario, Canada _(43.7064, -79.3986)_
  - Alyssa Schleifer — (CONTACT) — 416-603-5800 — alyssa.schleifer@uhn.ca
  - Tasnuva Hoque — (CONTACT) — 416-603-5800 — tasnuva.hoque@uhn.ca

---

*Canonical: https://parkinsonspathways.com/trial/NCT07417280*  
*HTML version: https://parkinsonspathways.com/trial/NCT07417280*  
*Source data: https://clinicaltrials.gov/study/NCT07417280*